Scientists unravel the structure of common bacterial wall-building protein, setting stage for new antibacterial therapies
The wall that surrounds bacteria to shield them from external assaults has long been a tantalizing target for drug therapies. Indeed, some of modern medicine’s most reliable antibiotics disarm harmful bacteria by disrupting the proteins that build their protective armor.
<iframe src=”https://player.vimeo.com/video/262243190″ width=”640″ height=”360″ frameborder=”0″ webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>
For decades, scientists knew of only one wall-making protein family. Then, in 2016, a team of Harvard Medical School scientists discovered that a previously unsuspected family of proteins that regulate cell division and cell shape had a secret skill: building bacterial walls.
Now, in another scientific first described March 28 in Nature, members of the same research team have revealed the molecular building blocks—and a structural weak spot—of a key member of that family.
“Our latest findings reveal the molecular structure of RodA and identify targetable spots where new antibacterial drugs could bind and subvert its work,” said study senior investigator Andrew Kruse, associate professor of biological chemistry and molecular pharmacology at Harvard Medical School.
The newly profiled protein, RodA, belongs to a family collectively known as SEDS proteins, present in nearly all bacteria. SEDS” near-ubiquity renders these proteins ideal targets for the development of broad-spectrum antibiotics to disrupt their structure and function, effectively neutralizing a range of harmful bacteria.
A weak link
In their earlier work, the scientists showed that RodA builds the cellular wall by knitting together large sugar molecules with clusters of amino acids. Once constructed, the wall encircles the bacterium, keeping it structurally intact, while repelling toxins, drugs and viruses.
The latest findings, however, go a step further and pinpoint a potential weak link in the protein’s makeup.
Specifically, the protein’s molecular profile reveals structural features reminiscent of other proteins whose architecture Kruse has disassembled. Among them, the cell receptors for the neurotransmitters acetylcholine and adrenaline, which are successfully targeted by medications that boost or stem the levels of these nerve-signaling chemicals to treat a range of conditions, including cardiac and respiratory diseases.
One particular feature caught the scientists’ attention—a pocket-like cavity facing the outer surface of the protein. The size and shape of the cavity, along with the fact that it is accessible from the outside, make it a particularly appealing drug target, the researchers said.
“What makes us excited is that this protein has a fairly discrete pocket that looks like it could be easily and effectively targeted with a drug that binds to it and interferes with the protein’s ability to do its job,” said study co-senior author David Rudner, professor of microbiology and immunobiology at Harvard Medical School.
In a set of experiments, researchers altered the structure of RodA in two bacterial species—the textbook representatives of the two broad classes that make up most of disease-causing bacteria. One of them was Escherichia coli, which belongs to a class of organisms with a double-cell membrane known as gram-negative bacteria, so named due to a reaction to staining test used in microbiology. The other bacterium was Bacillus subtilis, a single-membrane organism that belongs to so-called gram-positive bacteria.
When researchers induced even mild alterations to the structure of RodA’s cavity, the protein lost its ability to perform its work. E. coli and B. subtilis cells with disrupted RodA structure rapidly enlarged and became misshapen, eventually bursting and leaking their contents.
“A chemical compound—an inhibitor—that binds to this pocket would interfere with the protein’s ability to synthesize and maintain the bacterial wall,” Rudner said. “That would, in essence, crack the wall, weaken the cell and set off a cascade that eventually causes it to die.”
Additionally, because the protein is highly conserved across all bacterial species, the discovery of an inhibiting compound means that, at least in theory, a drug could work against many kinds of harmful bacteria.
“This highlights the beauty of super-basic scientific discovery,” said co-investigator Thomas Bernhardt, professor of microbiology and immunobiology at Harvard Medical School. “You get to the most fundamental level of things that are found across all species, and when something works in one of them, chances are it will work across the board.”
Solving for X
To determine RodA’s structure, scientists used a visualization technique known as X-ray crystallography, which reveals the molecular architecture of protein crystals based on a pattern of scattered X-ray beams. The technique requires two variables—the intensity of scattered X-rays and a so-called “phase angle,” a property related to the configuration of the atoms in a protein. The latter is measured indirectly, typically by using a closely related protein as a substitute to calculate the variable.
In this case, however, the team had on its hands a never-before-described protein with no known molecular siblings.
“In most cases you can use a related structure and bootstrap to a solution,” Kruse said. “In this case, we couldn’t do that. We had to predict what RodA looked like without any prior information about it.”
They needed a new way to solve for X.
In a creative twist, researchers turned to evolution and predictive analytics. Working with Debora Marks, assistant professor of systems biology at Harvard Medical School, they constructed a virtual model of the RodA’s folding pattern by analyzing the sequences of its closest evolutionary cousins.
The success of this “roundabout” approach, researchers said, circumvents a significant hurdle in field of structural biology and can open the doors toward defining the structures of many more newly discovered proteins.
“These insights underscore the importance of creative crosspollination among scientists from multiple disciplines and departments,” said study first author Megan Sjodt, a research fellow in biological chemistry and molecular pharmacology at Harvard Medical School. “We believe our results set the stage for subsequent work toward the discovery and optimization of new classes of antibiotics.”
Learn more: A Chink in Bacteria’s Armor
The Latest on: Antibiotics
via Google News
The Latest on: Antibiotics
- Nearly half of outpatient antibiotics prescribed without infection diagnosis, study finds on October 9, 2018 at 6:07 pm
One in five antibiotic prescriptions are provided without an in-person visit, and about half of outpatient antibiotics are prescribed without an infection-related diagnosis, according to a study prese... […]
- Recovering from a heart attack? Hold the antibiotics on October 9, 2018 at 6:48 am
The community of microorganisms that live in the human gut has been shown to confer all kinds of health benefits. Now, an international team of researchers has shown in mice that a healthy gut ... […]
- Antibiotics for appendicitis? Surgery often not needed on October 8, 2018 at 1:13 pm
CHICAGO — When emergency tests showed the telltale right-sided pain in Heather VanDusen's abdomen was appendicitis, she figured she'd be quickly wheeled into surgery. But doctors offered her the optio... […]
- Are Antibiotics Safe for Athletes? on October 8, 2018 at 12:58 pm
If an athlete must use antibiotics for an infection, what steps can he take to limit the damage to his healthy gut biome? Should he take priobiotics? What about prebiotics? How much of these and ... […]
- Top 5 New Antibiotics Advance to Fight Resistant Infections on October 8, 2018 at 12:12 pm
SAN FRANCISCO — Five standout antibiotics were featured during a pipeline session here at IDWeek 2018. The application process was open to all companies and the agents selected had the most novel data ... […]
- BI Program Celebrates Dairy Producers for Judicious Use of Antibiotics on October 8, 2018 at 9:46 am
Jami Schultze of Maple Ridge Dairy in Stratford, Wisconsin, was chosen as the grand prize winner for the Boehringer Ingelheim Producers for Progress recognition program. ( Boehringer Ingelheim ) Boehr... […]
- Novel functional insight in protein complex, possible new target for antibiotics on October 8, 2018 at 2:01 am
The protein complex (red) in the bacterial outer membrane. Credit: Utrecht University Faculty of Science Researchers at Utrecht University have gained new insights into the structure and function ... […]
- Antibiotics May Treat Appendicitis Without Surgery on October 4, 2018 at 5:33 pm
When a patient presents at the hospital with appendicitis, the standard course of action is to remove the appendix in an emergency surgery. But as the Associated Press reports, a new study published i... […]
- Patients Give Doctors High Marks For Prescribing Antibiotics For Common Sniffles on October 3, 2018 at 2:00 am
When they're sick, it seems Americans know what they want: antibiotics. And if they don't get them, their doctors' reputations may suffer. A study published Monday finds that patients rated themselves ... […]
via Bing News